Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 2/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.39 |
| ▸ | RARG | P13631 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12781654 | 0.92 | CYP3A4 (0.68) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL13939800 | 0.92 | ALOX15 (0.68) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL398164 | 0.92 | CYP3A4 (0.74) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL12781707 | 0.89 | HPGD (0.53) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL85484 | 0.85 | LMNA (0.55) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL12401770 | 0.85 | LMNA (0.55) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL23665988 | 0.84 | LMNA (0.53) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL5082769 | 0.84 | ALOX15 (0.84) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL12401755 | 0.84 | LMNA (0.53) | CYP3A4ALOX15LMNATP53HPGD | |
| SCHEMBL13169383 | 0.84 | LMNA (0.53) | CYP3A4ALOX15LMNATP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283501-A | Preparation of novel biphenyl tetradentate phosphonite ligand and application of ligand in mixed/etherified carbon tetrahydroformylation reaction | 广东欧凯新材料有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-111909207-A | Preparation of novel biphenyl tetradentate phosphonite ligand and application of novel biphenyl tetradentate phosphonite ligand in mixed/ether post-carbon hydroformylation reaction | 惠州凯特立斯科技有限公司 | 2020-11-10 | — | — | CN | claimed |
| US-20090270470-A1 | Compounds I | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | claimed |
| EP-1881950-A1 | NEW COMPOUNDS I | AstraZeneca AB (SE) | 2008-01-30 | — | — | EP | claimed |
| WO-2006121391-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | claimed |
| CN-111909207-B | Preparation of novel biphenyl tetradentate phosphonite ligand and application of ligand in mixed/etherified carbon tetrahydroformylation reaction | 广东欧凯新材料有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116283501-A | Preparation of novel biphenyl tetradentate phosphonite ligand and application of ligand in mixed/etherified carbon tetrahydroformylation reaction | 广东欧凯新材料有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-111909207-A | Preparation of novel biphenyl tetradentate phosphonite ligand and application of novel biphenyl tetradentate phosphonite ligand in mixed/ether post-carbon hydroformylation reaction | 惠州凯特立斯科技有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-8232428-B2 | Polycationic compounds and uses thereof | PolyMedix,Inc. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8129566-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20090270470-A1 | Compounds I | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1881950-A1 | NEW COMPOUNDS I | AstraZeneca AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006121391-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270470-A1 | Compounds I | F12, F11, F5 | CYP3A4 133/4885ALOX15 2063/4885LMNA 869/4885 |
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | CYP3A4 4721/4885ALOX15 1107/4885LMNA 3716/4885 |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | GLRA1, GLRB, GPBAR1 | CYP3A4 716/4885ALOX15 1015/4885LMNA 2299/4885 |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | CYP3A4 4721/4885ALOX15 1107/4885LMNA 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.